RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
CNS Pharmaceuticals Stock

CNS Pharmaceuticals Stocks 2024

CNS Pharmaceuticals Stocks

75,350

Ticker

CNSP

ISIN

US18978H1023

WKN

A2PNH4

In 2024, CNS Pharmaceuticals had 75,350 outstanding stocks, a 0% change from the 75,350 stocks in the previous year.

The CNS Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2030e0.08
2029e0.08
2028e0.08
2027e0.08
2026e0.08
2025e0.08
2024e0.08
20230.08
20221.36
20210.88
20200.8
20190.45
20180.52
20170.52

CNS Pharmaceuticals shares outstanding

The number of shares was CNS Pharmaceuticals in 2023 — This indicates how many shares 75,350 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CNS Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CNS Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CNS Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CNS Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CNS Pharmaceuticals Aktienanalyse

What does CNS Pharmaceuticals do?

CNS Pharmaceuticals Inc is an American pharmaceutical company specializing in the development and marketing of innovative therapies for patients with severe and life-threatening central nervous system disorders. The company was founded in 2017 and is headquartered in Houston, Texas. CNS Pharmaceuticals Inc's history began with the realization that there is an urgent need for new and more effective treatment methods for central nervous system tumors. The company's founders therefore identified promising new drugs based on the latest research findings and began testing them in clinical trials. CNS Pharmaceuticals Inc's business model focuses on innovative research and development of new drugs, as well as close collaboration with leading scientists and medical professional societies. The company aims to bring its medications to market quickly and cost-effectively, without compromising on quality or safety. The various divisions of CNS Pharmaceuticals Inc include research, development, production, and marketing of its drugs. The company has launched a variety of research projects aimed at developing new therapies for patients with brain tumors and other severe central nervous system disorders. One of CNS Pharmaceuticals Inc's most well-known products is Berubicin, a promising drug for the treatment of glioblastoma, a particularly aggressive type of brain tumor. Berubicin is a novel DNA-intercalating drug that is highly effective and has low toxicity. Clinical trials have already shown that Berubicin can extend the survival time of patients. Another important product of CNS Pharmaceuticals Inc is WP1244, a drug against glioblastoma based on an innovative technology that improves the uptake of drugs into cells. Preclinical studies have already shown that WP1244 is able to stop tumor growth and destroy cancer cells. CNS Pharmaceuticals Inc has a strong network of partner companies and distribution partners that help with the marketing and dissemination of its products. The company works closely with leading cancer centers and research institutions to further improve the effectiveness of its drugs and provide patients with a higher level of safety and quality of life. Overall, CNS Pharmaceuticals Inc has established itself as a dynamic and innovative company with a high level of expertise in the development of new drugs. The company aims to expand its position as a leading provider of therapies for patients with brain tumors and other severe central nervous system disorders, and to sustainably improve the quality of life of affected patients. CNS Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating CNS Pharmaceuticals's Shares Outstanding

CNS Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in CNS Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding CNS Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in CNS Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about CNS Pharmaceuticals stock

How many stocks are there of CNS Pharmaceuticals?

The current number of stocks of CNS Pharmaceuticals is 75,350 undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of CNS Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of CNS Pharmaceuticals evolved in recent years?

The number of shares of CNS Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. CNS Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of CNS Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does CNS Pharmaceuticals pay?

Over the past 12 months, CNS Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CNS Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of CNS Pharmaceuticals?

The current dividend yield of CNS Pharmaceuticals is .

When does CNS Pharmaceuticals pay dividends?

CNS Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CNS Pharmaceuticals?

CNS Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of CNS Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CNS Pharmaceuticals located?

CNS Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von CNS Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CNS Pharmaceuticals from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did CNS Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of CNS Pharmaceuticals in the year 2023?

In the year 2023, CNS Pharmaceuticals distributed 0 USD as dividends.

In which currency does CNS Pharmaceuticals pay out the dividend?

The dividends of CNS Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CNS Pharmaceuticals

Our stock analysis for CNS Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CNS Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.